Health4 hours ago
SUPRAME Trial Advances TCR Therapy for Cutaneous Melanoma
The phase 3 SUPRAME trial, focusing on the PRAME-directed T-cell receptor (TCR) therapy IMA203, is making significant strides in treating patients with unresectable or metastatic cutaneous...